Laparoscopic Power Morcellators Market: as the FDA's containment device requirement continues to structurally cap the US market around a single compliant vendor, this remains one of the most regulatory-locked device categories in gynaecological surgery, where the constraint itself, not innovation or competitive entry, is the primary driver of market structure.

The global laparoscopic power morcellators market size was USD 148 Million in 2025 and is expected to register a revenue CAGR of 6.3% during the forecast period.Market revenue growth is driven by continued demand for minimally invasive gynaecological surgery as an alternative to open abdominal hysterectomy and open myomectomy, combined with the regulatory evolution toward FDA-required contained morcellation.The FDA updated its Safety Communication on December 29, 2020 to recommend that when morcellation is clinically appropriate, only contained morcellation should be performed, with a boxed warning noting that approximately 1 in 350 women undergoing hysterectomy or myomectomy for fibroids has an unsuspected uterine sarcoma.The FDA's final guidance requiring all power morcellators marketed in the US to be used only with a compatible FDA-cleared containment device established the regulatory framework that defines the contained morcellation commercial market.Olympus confirmed that its PneumoLiner is the only 510(k)-cleared containment device for morcellation of gynecological tissue, and subsequently launched the moresolution Power Morcellator, manufactured by TROKAMED GmbH, which together with the PneumoLiner forms the Olympus Contained Tissue Extraction System.These are some of the key factors driving revenue growth of the market.

A second layer of context, distinct from most device categories in this coverage, is that this market's structure is defined primarily by a persistent regulatory constraint rather than by competitive innovation, so revenue growth here compounds through gradual expansion of the eligible patient population and procedure setting rather than through new entrants or technology displacement.Because the FDA's containment device requirement has effectively limited US commercial competition to a single compliant contained tissue extraction system since 2016, growth in this market depends on the number of eligible pre-menopausal, non-malignant fibroid patients electing minimally invasive treatment and the number of ambulatory surgical centres building contained morcellation capability, rather than on a widening competitive field.As a result, Clarivant's research found no new FDA clearances, competitive market entries, or containment device approvals in the twelve months to Q2 2026 specific to this category, consistent with the structural, regulatory-defined stability that has characterised this market since the FDA's 2020 Safety Communication.The most recent substantive US regulatory development remains the FDA's May 26, 2023 final guidance, Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures, which provides manufacturers with non-clinical performance testing recommendations for future 510(k) submissions but has not yet produced a second cleared competitor to the Olympus system.These are the key factors defining the structure and growth trajectory of the market.

Because the FDA boxed warning permanently excludes peri- and postmenopausal women and women with suspected malignancy from eligible patient populations, this structurally caps the addressable market regardless of demand for minimally invasive gynaecological surgery more broadly.

The approximately 1 in 350 unsuspected uterine sarcoma risk is a second constraint, creating irreducible liability uncertainty that deters many gynaecological surgeons from offering morcellation even within the compliant contained system framework.

The highly restricted patient selection framework is a third constraint, where only pre-menopausal women with symptomatic non-malignant fibroids who are not candidates for vaginal or mini-laparotomy tissue removal are eligible for contained morcellation.

These factors substantially constrain laparoscopic power morcellators market growth over the forecast period.

The clearest driver of demand is the regulatory framework itself, which has channelled all compliant US demand toward a single manufacturer's platform. A morcellation device category only sustains commercial viability under a containment mandate if a compliant device actually exists, and Olympus's PneumoLiner, cleared as the first-of-its-kind containment system in April 2016, has remained the only device meeting that requirement for the US market. Olympus confirmed that its PneumoLiner is the only 510(k)-cleared containment device for morcellation of gynecological tissue as recommended by the FDA, with the FDA final guidance requiring all power morcellators currently marketed in the United States to be used only with a compatible FDA-cleared containment device. A study examining the impact of the FDA's original 2014 warning found that hospitals that had banned morcellation saw complication risk increase as cases shifted toward open abdominal hysterectomy, providing the clinical rationale supporting continued access to compliant contained morcellation. The effect on the market is that Olympus's commercial position is protected by regulatory structure rather than by competitive differentiation alone, a distinctive dynamic among the device categories Clarivant covers. These are some of the key factors driving revenue growth of the market.

The second driver, more accurately described as a stabilising constraint, is the FDA's precisely defined eligible patient population that has not materially widened or narrowed since the 2020 Safety Communication. A restricted-eligibility device category only grows in line with the growth of its eligible population, and the eligible population for contained morcellation, pre-menopausal women with symptomatic non-malignant fibroids who are not candidates for vaginal or mini-laparotomy removal, tracks demographic and fibroid incidence trends rather than expanding through new clinical indications. The FDA's May 26, 2023 final guidance on non-clinical performance assessment of tissue containment systems provided manufacturers with testing recommendations for future 510(k) submissions but has not, as of the most recent verified information, produced a second FDA-cleared competitor to the Olympus system. Clarivant's research identified no new FDA clearances, competitive entries, or safety communications specific to this category in the twelve months to Q2 2026. The effect on the market is that revenue growth remains steady and predictable, tracking the growth in eligible patient volume and expanding ambulatory surgical centre adoption rather than reflecting competitive or technological disruption. These are some of the key factors driving revenue growth of the market.

“The FDA's containment device requirement has channelled all compliant US demand toward a single manufacturer's platform since 2016, making this one of the most regulatory-defined market structures among the device categories Clarivant covers.”

However, the laparoscopic power morcellators market faces profound structural constraints from the FDA boxed warning, irreducible uterine sarcoma risk, and highly restricted patient selection criteria.

Because the FDA boxed warning permanently excludes peri- and postmenopausal women and women with suspected malignancy, the addressable market is structurally capped regardless of broader minimally invasive gynaecological surgery demand.

The approximately 1 in 350 unsuspected uterine sarcoma risk is a second constraint, creating ongoing medicolegal liability uncertainty for surgeons offering contained morcellation.

The highly restricted patient selection framework, limiting eligibility to pre-menopausal women with symptomatic non-malignant fibroids who are not candidates for alternative tissue removal, is a third constraint on total procedure volume.

These factors substantially constrain laparoscopic power morcellators market growth over the forecast period.

Based on application, the global laparoscopic power morcellators market is segmented into hysterectomy and myomectomy. Hysterectomy accounts for the dominant revenue share at approximately 68% of 2025 market revenue. Myomectomy is expected to register the fastest revenue growth rate over the forecast period, driven by growing preference for fertility-preserving fibroid surgery among pre-menopausal women with fibroids who wish to preserve uterine function.

Based on end-use, the global laparoscopic power morcellators market is segmented into hospitals and speciality gynaecology centres, and ambulatory surgical centres. Hospitals account for the dominant revenue share at approximately 80% of 2025 market revenue. Ambulatory surgical centres are expected to register the fastest revenue growth rate as contained morcellation capability expands to outpatient settings with experienced minimally invasive gynaecologists.

Based on regional analysis, the laparoscopic power morcellators market in North America accounted for the largest revenue share in 2025 at approximately 38% of global revenue. The Olympus PneumoLiner as the only FDA 510(k)-cleared containment device, and the FDA final guidance requiring all US morcellators to be used only with a compatible FDA-cleared containment device, establish the North American market as defined entirely by the Olympus Contained Tissue Extraction System.

The market in Europe is expected to register a steady revenue growth rate in the global laparoscopic power morcellators market over the forecast period.

Germany, France, the United Kingdom, and Italy represent the four largest national morcellator markets within Europe. European contained morcellation follows the EU Medical Device Regulation framework incorporating CE-marked containment device requirements similar in spirit to the FDA's finalized guidance, with LiNA Medical's PowerBlade morcellator and other European manufacturers competing alongside the Olympus Contained Tissue Extraction System.

The market in Asia Pacific is expected to register the fastest revenue growth rate in the global laparoscopic power morcellators market over the forecast period.

China, Japan, South Korea, India, and Australia represent the five largest national morcellator markets. The Asia Pacific regulatory framework varies by country and does not uniformly require the contained morcellation FDA-cleared bag equivalent that applies in the US market, creating a different commercial adoption profile where uncontained morcellation may remain available in some jurisdictions under surgeon discretion.

Latin America and Middle East and Africa markets are expected to register moderate revenue growth rates in the global laparoscopic power morcellators market over the forecast period.

Brazil and Mexico represent primary Latin America commercial markets, with growing gynaecological minimally invasive surgery adoption. Saudi Arabia and the UAE represent primary Middle East and Africa commercial markets, with growing GCC hospital adoption driving contained morcellation system procurement at new tertiary gynaecology centres.